drugset / Trial / NCT04702581
A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery
RandomizedParallel-groupOpen-labelTreatment
Summary
Because of their prolonged survival, patients with 1p/19q-codeleted low-grade oligodendrogliomas treated with RT + PCV are at risk of neurocognitive deterioration. We make the hypothesis that withholding radiotherapy until tumor progression could reduce the risk of neurocognitive deterioration without impairing overall survival.
Timeline
- Start
- 2021-12-07
- Primary completion
- 2030-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Lomustine | Small molecule | 110 mg/m2 | Oral |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |
| Background | procarbazine | Small molecule | 60 mg/m2 | Oral |